Cell therapy (NK cells) · Immune activation · developed by Inmune Bio
INKmune is a suspension of INB16 cells rendered replication incompetent, designed to prime and activate natural killer (NK) cells in vivo to achieve tumor cell lysis. It is being studied in cancer, including metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06056791 | Phase 1/2 | Cancer | Completed | INMB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancermCRPCMetastatic Castration-resistant Prostate Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the INMB page.
See INMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INMB catalysts and pipeline →